Scarica l'app Stockscreener
9.67
3.42%
0.32
Pre-mercato:
9.76
0.09
+0.93%
Precedente Chiudi:
$9.35
Aprire:
$9.15
Volume 24 ore:
697.70K
Relative Volume:
0.67
Capitalizzazione di mercato:
$303.20M
Reddito:
$19.09M
Utile/perdita netta:
$-82.13M
Rapporto P/E:
-3.4504
EPS:
-2.8026
Flusso di cassa netto:
$-70.00M
1 W Prestazione:
+8.17%
1M Prestazione:
-29.31%
6M Prestazione:
-79.99%
1 anno Prestazione:
-62.09%
Intervallo 1D:
$9.15
$10.08
Intervallo di 1 settimana:
$8.25
$10.12
Portata 52W:
$8.25
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
9.67 | 303.20M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
Insider Spends US$251k Buying More Shares In LENZ Therapeutics - moomoo.com
LENZ Therapeutics: Speculative But Strong Buy (NASDAQ:LENZ) - Seeking Alpha
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares - simplywall.st
President of LENZ Therapeutics Picks Up 57% More Stock - Yahoo Finance
Tech Rally: What is the cash position of LENZ Therapeutics Inc2026 Technical Patterns & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Institution Moves: Is LENZ Therapeutics Inc a strong candidate for buy and holdProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Insider Buying: Jeffrey George Acquires Shares of LENZ Therapeutics Inc (LENZ) - GuruFocus
Lenz Therapeutics CFO Chevallard buys $64k in stock By Investing.com - Investing.com Australia
Lenz Therapeutics director George buys $49,890 in stock By Investing.com - Investing.com Canada
Lenz Therapeutics CEO Schimmelpennink buys $251k in stock By Investing.com - Investing.com Canada
Lenz Therapeutics Insider Bought Shares Worth $251,411, According to a Recent SEC Filing - MarketScreener
Lenz Therapeutics director George buys $49,890 in stock - Investing.com
Lenz Therapeutics CFO Chevallard buys $64k in stock - Investing.com
Director at LENZ Therapeutics (LENZ) buys 5,592 shares in open-market trade - stocktitan.net
LENZ Therapeutics (LENZ) CEO adds 28,089 shares in open-market stock purchase - stocktitan.net
LENZ Therapeutics (LENZ) CFO buys 7,500 shares of stock - stocktitan.net
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles - marketsmojo.com
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers - simplywall.st
The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically - Yahoo Finance
Lenz Therapeutics Earnings Call: High Spend, Growing Traction - TipRanks
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance - Markets Mojo
LENZ Therapeutics Hits 52-Week Low at $8.86 Amid Ongoing Struggles - Markets Mojo
LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade) - Seeking Alpha
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week - Yahoo Finance
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Positive Forecast for LENZ Earnings - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
LENZ Therapeutics (NASDAQ:LENZ) Price Target Lowered to $26.00 at Citigroup - Defense World
Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst - MarketBeat
Valuation Update: What is the cash position of LENZ Therapeutics Inc2026 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com UK
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright By Investing.com - Investing.com Australia
LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum - VisionMonday.com
VIZZ by LENZ Therapeutics: FDA-Approved Once-Daily Eye Drop for Presbyopia Treatment and Market Opportunity 32 - Minichart
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
LENZ Therapeutics 2025 10-K: $19.1M Revenue, $(2.85) EPS - TradingView
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M - TradingView
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses - Investing.com UK
LENZ Therapeutics Reports Q4 and Full Year 2025 Results; Launches VIZZ Eye Drop for Presbyopia with Strong Prescription Uptake and Expanding Commercial Infrastructure - Minichart
LENZ Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Why Lenz Therapeutics Stock Crashed Today - The Globe and Mail
LENZ Therapeutics Q4 Earnings Call Highlights - MarketBeat
LENZ: Strong launch momentum, robust cash, and expanding adoption position the product for growth - TradingView
Why Lenz Therapeutics Stock Crashed Today - The Motley Fool
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch - ChartMill
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):